Staar Surgical Company Receives a Buy from Canaccord Genuity

Canaccord Genuity analyst Jason Mills maintained a Buy rating on Staar Surgical Company (NASDAQ: STAA) today and set a price target of $23. The company’s shares opened today at $17.05.

According to TipRanks.com, Mills is a top 25 analyst with an average return of 24.0% and a 78.0% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Boston Scientific Corp, and Merit Medical Systems.

Currently, the analyst consensus on Staar Surgical Company is Strong Buy and the average price target is $22, representing a 29.0% upside.

In a report issued on April 30, William Blair also upgraded the stock to Buy.

See today’s analyst top recommended stocks >>

The company has a one-year high of $22.60 and a one-year low of $8.95. Currently, Staar Surgical Company has an average volume of 110.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

STAAR Surgical Co. engages in the development, manufacture, production, market, and trade of implantable lenses for the eye and delivery systems. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Monrovia, CA.